newsfilter
← Latest News
GlobeNewswire·

Marker Therapeutics Awarded $2.6 Million FDA Orphan Products Development Grant to Advance MT-601 in Pancreatic Cancer

HOUSTON, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (NASDAQ:MRKR), is a clinical-stage immuno-oncology company developing multi-antigen recognizing (MAR)-T cell therapies under an exclusive worldwide